Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Olopatadine is a selective histamine H1 antagonist and mast cell stabilizer used primarily to treat allergic conjunctivitis (itchy eyes due to allergies) and allergic rhinitis. It works by blocking the effects of histamine—a key mediator in allergic reactions—at the H1 receptor and by stabilizing mast cells to prevent the release of inflammatory mediators such as tryptase and prostaglandin D2. Olopatadine is available as ophthalmic solutions for eye symptoms (e.g., itching or redness from pollen or animal dander) and as a nasal spray for seasonal allergic rhinitis. The drug was first approved in 1996 (ophthalmic) in the US and EU. Compared with corticosteroid eye drops, olopatadine offers relief with fewer side effects related to intraocular pressure or infection risk[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on olopatadine.